In the BioHarmony Drug Report Database
Pramlintide
Symlin (pramlintide) is a protein pharmaceutical. Pramlintide was first approved as Symlin on 2005-03-16. It is used to treat type 1 diabetes mellitus and type 2 diabetes mellitus in the USA. It is known to target calcitonin receptor.
Trade Name
|
Symlin |
|---|---|
Common Name
|
pramlintide |
ChEMBL ID
|
CHEMBL2103758 |
Indication
|
type 1 diabetes mellitus, type 2 diabetes mellitus |
Drug Class
|
Peptides: amylin derivatives or mimics |
Image (chem structure or protein)